A citation-based method for searching scientific literature

Rafal Dziadziuszko, Matthew G Krebs, Filippo De Braud, Salvatore Siena, Alexander Drilon, Robert C Doebele, Manish R Patel, Byoung Chul Cho, Stephen V Liu, Myung-Ju Ahn, Chao-Hua Chiu, Anna F Farago, Chia-Chi Lin, Christos S Karapetis, Yu-Chung Li, Bann-Mo Day, David Chen, Timothy R Wilson, Fabrice Barlesi. J Clin Oncol 2021
Times Cited: 5







List of co-cited articles
4 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non-Small-Cell Lung Cancer.
Justin F Gainor, Diane Tseng, Satoshi Yoda, Ibiayi Dagogo-Jack, Luc Friboulet, Jessica J Lin, Harper G Hubbeling, Leila Dardaei, Anna F Farago, Katherine R Schultz,[...]. JCO Precis Oncol 2017
120
40

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
Alexander Drilon, Salvatore Siena, Rafal Dziadziuszko, Fabrice Barlesi, Matthew G Krebs, Alice T Shaw, Filippo de Braud, Christian Rolfo, Myung-Ju Ahn, Jürgen Wolf,[...]. Lancet Oncol 2020
112
40

Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein.
Holger Fischer, Mohammed Ullah, Cecile C de la Cruz, Thomas Hunsaker, Claudia Senn, Thomas Wirz, Björn Wagner, Dragomir Draganov, Faye Vazvaei, Massimiliano Donzelli,[...]. Neuro Oncol 2020
15
40

Crizotinib in ROS1-rearranged non-small-cell lung cancer.
Alice T Shaw, Sai-Hong I Ou, Yung-Jue Bang, D Ross Camidge, Benjamin J Solomon, Ravi Salgia, Gregory J Riely, Marileila Varella-Garcia, Geoffrey I Shapiro, Daniel B Costa,[...]. N Engl J Med 2014
40

Larotrectinib for the treatment of TRK fusion solid tumors.
Theodore W Laetsch, Douglas S Hawkins. Expert Rev Anticancer Ther 2019
14
20

Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumors.
Georgina Meneses-Lorente, Darren Bentley, Elena Guerini, Karey Kowalski, Edna Chow-Maneval, Li Yu, Andreas Brink, Nassim Djebli, Francois Mercier, Vincent Buchheit,[...]. Invest New Drugs 2021
3
33


Systematic review of neurotrophic tropomyosin-related kinase inhibition as a tumor-agnostic management strategy.
Paula Chu, Sarah Batson, Matthew Hodgson, Catherine R Mitchell, Anna Steenrod. Future Oncol 2020
3
33


Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.
Mariangela Russo, Sandra Misale, Ge Wei, Giulia Siravegna, Giovanni Crisafulli, Luca Lazzari, Giorgio Corti, Giuseppe Rospo, Luca Novara, Benedetta Mussolin,[...]. Cancer Discov 2016
171
20

Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.
David S Hong, Steven G DuBois, Shivaani Kummar, Anna F Farago, Catherine M Albert, Kristoffer S Rohrberg, Cornelis M van Tilburg, Ramamoorthy Nagasubramanian, Jordan D Berlin, Noah Federman,[...]. Lancet Oncol 2020
184
20

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Robert C Doebele, Alexander Drilon, Luis Paz-Ares, Salvatore Siena, Alice T Shaw, Anna F Farago, Collin M Blakely, Takashi Seto, Byung Chul Cho, Diego Tosi,[...]. Lancet Oncol 2020
301
20

The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib.
Tejas Patil, Derek E Smith, Paul A Bunn, Dara L Aisner, Anh T Le, Mark Hancock, William T Purcell, Daniel W Bowles, D Ross Camidge, Robert C Doebele. J Thorac Oncol 2018
56
20

Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors.
Dazhi Liu, Michael Offin, Stephen Harnicar, Bob T Li, Alexander Drilon. Ther Clin Risk Manag 2018
45
20

Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020).
Liling Huang, Shiyu Jiang, Yuankai Shi. J Hematol Oncol 2020
36
20

New strategies in personalized medicine for solid tumors: molecular markers and clinical trial designs.
Juliane M Jürgensmeier, Joseph P Eder, Roy S Herbst. Clin Cancer Res 2014
21
20

Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an NTRK Gene Fusion.
Anna F Farago, Martin S Taylor, Robert C Doebele, Viola W Zhu, Shivaani Kummar, Alexander I Spira, Theresa A Boyle, Eric B Haura, Maria E Arcila, Ryma Benayed,[...]. JCO Precis Oncol 2018
80
20

Matching-adjusted indirect comparison: entrectinib versus crizotinib in ROS1 fusion-positive non-small cell lung cancer.
Paula Chu, Miranta Antoniou, Mohit K Bhutani, Amine Aziez, Monica Daigl. J Comp Eff Res 2020
2
50

Molecular characterization of cancers with NTRK gene fusions.
Zoran Gatalica, Joanne Xiu, Jeffrey Swensen, Semir Vranic. Mod Pathol 2019
185
20

Management of brain metastases according to molecular subtypes.
Riccardo Soffietti, Manmeet Ahluwalia, Nancy Lin, Roberta Rudà. Nat Rev Neurol 2020
27
20

Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.
Maria Menichincheri, Elena Ardini, Paola Magnaghi, Nilla Avanzi, Patrizia Banfi, Roberto Bossi, Laura Buffa, Giulia Canevari, Lucio Ceriani, Maristella Colombo,[...]. J Med Chem 2016
115
20

Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in ETV6-NTRK3-Positive Acute Myeloid Leukemia.
Kristen M Smith, Patrick C Fagan, Elena Pomari, Giuseppe Germano, Chiara Frasson, Colin Walsh, Ian Silverman, Paolo Bonvini, Gang Li. Mol Cancer Ther 2018
21
20

Resistance to TRK inhibition mediated by convergent MAPK pathway activation.
Emiliano Cocco, Alison M Schram, Amanda Kulick, Sandra Misale, Helen H Won, Rona Yaeger, Pedram Razavi, Ryan Ptashkin, Jaclyn F Hechtman, Eneda Toska,[...]. Nat Med 2019
68
20

Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond?
Kartik Sehgal, Andrew J Piper-Vallillo, Hollis Viray, Adeel M Khan, Deepa Rangachari, Daniel B Costa. Precis Cancer Med 2020
8
20

What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).
A Drilon, G Li, S Dogan, M Gounder, R Shen, M Arcila, L Wang, D M Hyman, J Hechtman, G Wei,[...]. Ann Oncol 2016
170
20

NTRK fusion-positive cancers and TRK inhibitor therapy.
Emiliano Cocco, Maurizio Scaltriti, Alexander Drilon. Nat Rev Clin Oncol 2018
426
20

Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer.
Bo Mi Ku, Yeon Hee Bae, Kyoung Young Lee, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn. Invest New Drugs 2020
16
20

The current state of molecular testing in the treatment of patients with solid tumors, 2019.
Wafik S El-Deiry, Richard M Goldberg, Heinz-Josef Lenz, Anthony F Shields, Geoffrey T Gibney, Antoinette R Tan, Jubilee Brown, Burton Eisenberg, Elisabeth I Heath, Surasak Phuphanich,[...]. CA Cancer J Clin 2019
85
20


Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.
Elena Ardini, Maria Menichincheri, Patrizia Banfi, Roberta Bosotti, Cristina De Ponti, Romana Pulci, Dario Ballinari, Marina Ciomei, Gemma Texido, Anna Degrassi,[...]. Mol Cancer Ther 2016
152
20

Discovery of potent and selective inhibitors of the mammalian target of rapamycin (mTOR) kinase.
Pawel Nowak, Derek C Cole, Natasja Brooijmans, Matthew G Bursavich, Kevin J Curran, John W Ellingboe, James J Gibbons, Irwin Hollander, YongBo Hu, Joshua Kaplan,[...]. J Med Chem 2009
46
20

AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity.
Christine M Chresta, Barry R Davies, Ian Hickson, Tom Harding, Sabina Cosulich, Susan E Critchlow, John P Vincent, Rebecca Ellston, Darren Jones, Patrizia Sini,[...]. Cancer Res 2010
562
20

Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases.
Pascale Tomasini, Julie Egea, Maxime Souquet-Bressand, Laurent Greillier, Fabrice Barlesi. Ther Adv Respir Dis 2019
17
20


Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor.
Robert Mallon, Irwin Hollander, Larry Feldberg, Judy Lucas, Veronica Soloveva, Aranapakam Venkatesan, Christoph Dehnhardt, Efren Delos Santos, Zecheng Chen, Osvaldo Dos Santos,[...]. Mol Cancer Ther 2010
48
20

(S)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR Kinase.
Denise Rageot, Thomas Bohnacker, Erhan Keles, Jacob A McPhail, Reece M Hoffmann, Anna Melone, Chiara Borsari, Rohitha Sriramaratnam, Alexander M Sele, Florent Beaufils,[...]. J Med Chem 2019
19
20


Phosphoinositide 3-kinase in disease: timing, location, and scaffolding.
Matthias P Wymann, Romina Marone. Curr Opin Cell Biol 2005
163
20

mTOR: from growth signal integration to cancer, diabetes and ageing.
Roberto Zoncu, Alejo Efeyan, David M Sabatini. Nat Rev Mol Cell Biol 2011
20

Development of ATP-competitive mTOR inhibitors.
Qingsong Liu, Seong A Kang, Carson C Thoreen, Wooyoung Hur, Jinhua Wang, Jae Won Chang, Andrew Markhard, Jianming Zhang, Taebo Sim, David M Sabatini,[...]. Methods Mol Biol 2012
25
20


Long-term treatment of epilepsy with everolimus in tuberous sclerosis.
Darcy A Krueger, Angus A Wilfong, Maxwell Mays, Christina M Talley, Karen Agricola, Cindy Tudor, Jamie Capal, Katherine Holland-Bouley, David Neal Franz. Neurology 2016
68
20

Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors.
B Markman, J Tabernero, I Krop, G I Shapiro, L Siu, L C Chen, M Mita, M Melendez Cuero, S Stutvoet, D Birle,[...]. Ann Oncol 2012
106
20

Lead optimization of N-3-substituted 7-morpholinotriazolopyrimidines as dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors: discovery of PKI-402.
Christoph M Dehnhardt, Aranapakam M Venkatesan, Efren Delos Santos, Zecheng Chen, Osvaldo Santos, Semiramis Ayral-Kaloustian, Natasja Brooijmans, Robert Mallon, Irwin Hollander, Larry Feldberg,[...]. J Med Chem 2010
50
20


Expanding mTOR signaling.
Qian Yang, Kun-Liang Guan. Cell Res 2007
399
20


5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.
Florent Beaufils, Natasa Cmiljanovic, Vladimir Cmiljanovic, Thomas Bohnacker, Anna Melone, Romina Marone, Eileen Jackson, Xuxiao Zhang, Alexander Sele, Chiara Borsari,[...]. J Med Chem 2017
62
20




Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.